CN108619493A - A kind of capsule increasing bone density - Google Patents
A kind of capsule increasing bone density Download PDFInfo
- Publication number
- CN108619493A CN108619493A CN201810630676.7A CN201810630676A CN108619493A CN 108619493 A CN108619493 A CN 108619493A CN 201810630676 A CN201810630676 A CN 201810630676A CN 108619493 A CN108619493 A CN 108619493A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- bone
- capsule
- bone density
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of capsules increasing bone density, and the capsule is by calcium carbonate, D aminoglucose hydrochlorides, chondroitin sulfate, bone collagen powder, vitamin K2, microcrystalline cellulose, magnesium stearate be made, the invention also discloses the preparation methods for the capsule for increasing bone density.The capsule of the increase bone density of the present invention has both calcium carbonate, D aminoglucose hydrochlorides, chondroitin sulfate, bone collagen powder, vitamin K2Various effects, suitable mid-aged population takes, and can increase the bone density of user.
Description
Technical field
The present invention relates to a kind of capsules, it particularly relates to a kind of capsule increasing bone density.
Background technology
Osteoporosis is a kind of osteopathy caused by many reasons, and bone tissue has normal calcification, and calcium salt is with matrix in just
Normal ratio, the metabolic bone disease with the characteristics of the reduction of unit volume inner bone tissues amount become.In most osteoporosises, bone tissue
It reduces caused by increasing mainly due to bone absorption.By skeleton pain, be easy to fracture characterized by.
Bone is made of 2/3 calcium salt and 1/3 ossein, and calcium keeps bone hard, and ossein allows bone rich in bullet
Property and toughness.Calcium salt and ossein, the two complement each other, and can just possess the bone for having both intensity and toughness.With the increasing at age
Long, what is be lost in bone not only has calcium, also ossein, and while bone density declines, bone can also become fragile, scientific research card
Real, the 80% of substance number of dropouts is ossein, 20% is calcium salt in bone, and bone loses the support of ossein, and bone structure becomes crisp
It is weak, and then cause osteoporosis, the even skeletal diseases such as fracture.Ossein is also known as " tectine matter ", is body bone tissue, closes
Save the constituent of cartilage, epiphyseal cartilage, bone trabecula.Therefore, it for the patient with bone disease of part, only replenishes the calcium often not enough, also
It must pay attention to and successfully manage the loss of ossein, could preferably avoid the generation of orthopaedic disease.
Invention content
For above-mentioned technical problem in the related technology, the present invention proposes a kind of capsule increasing bone density, can overcome
The above-mentioned deficiency of the prior art.
To realize the above-mentioned technical purpose, the technical proposal of the invention is realized in this way：
A kind of capsule increasing bone density, is grouped as by the group of following parts by weight：
160-220 parts of calcium carbonate
90-130 parts of D-Glucosamine Hydrochloride
50-80 parts of chondroitin sulfate
40-80 parts of bone collagen powder
The vitamin K that mass content is 0.2%2Powder3-8 parts
10-40 parts of microcrystalline cellulose
2-4 parts of magnesium stearate.
Preferably, the capsule for increasing bone density is grouped as by the group of following parts by weight：
210 parts of calcium carbonate
105 parts of D-Glucosamine Hydrochloride
60 parts of chondroitin sulfate
55 parts of bone collagen powder
The vitamin K that mass content is 0.2%25 parts of powder
12 parts of microcrystalline cellulose
3 parts of magnesium stearate.
According to another aspect of the present invention, the preparation method for providing the capsule for increasing bone density, includes the following steps：
（1）Sieving
By calcium carbonate, D-Glucosamine Hydrochloride, chondroitin sulfate, bone collagen powder, vitamin K2Mass content is
0.2% vitamin K2Powder, microcrystalline cellulose, magnesium stearate cross 60 mesh sieve respectively；
（2）Mixing
Calcium carbonate, D-Glucosamine Hydrochloride, chondroitin sulfate, bone collagen powder after sieving is placed in mixing machine and is mixed
It closes 15min and obtains mixed powder 1, by the vitamin K after sieving2Powder, microcrystalline cellulose, magnesium stearate, which are uniformly mixed, obtains mixed powder
2；Mixed powder 1 and mixed powder 2 are placed in mixing 20min in mixing machine and obtain total mixed powder；
（3）It is filling
By step（2）The filling capsule of the total mixed powder of gained, it is 0.45g/ to adjust loading amount.
The pharmacological action of each component in the capsule of the increase bone density of the present invention：
D-Glucosamine Hydrochloride is the chitosan oligosaccharide derivative that chitin obtains in hydrochloric acid through fully degraded, can promote human body
Glutinous polysaccharide synthesis, improves knuckle synovia stickiness, is conducive to the metabolism and reparation of articular cartilage, and have apparent anti-inflammatory analgesic to make
With with pharmacological actions such as anti-inflammatory, antitumor, immunological regulation, increase bone density, anti-corrosive antibacterials.
Calcium carbonate can make calcium tonic, and absorptivity is only second to calcium citrate malate and dissolves in hydrochloric acid in gastric juice up to 39%, it has also become dosage form at most,
Using most calcium tonics.
Chondroitin sulfate is to be covalently attached a kind of glycosaminoglycan that proteoglycans is formed on protein.Chondroitin sulfate is wide
The general extracellular matrix and cell surface for being distributed in animal tissue, sugar chain is by alternate glucuronic acid and N- acetylgalactosamines
（Also known as N- acetylamino galactosamines）Disaccharide unit forms, residual by a serine that seemingly sugared link zone is connected to core protein
On base.The medically drug as treatment joint disease, can improve range of motion, reduce the width of joint space, from
Fundamentally improve joint prob.
Bone collagen is a kind of fibrous protein in bone, and content can account for the 90% of bone organic matter, is a kind of life
Physical property macromolecule is the important substance for maintaining bone toughness and providing skeleton nutrition.In bone, the fiber that ossein is formed
Net also acts as the fixed function of similar bonding, is the binder of calcium hydroxy phosphate, the master of bone is collectively formed with calcium hydroxy phosphate
Body.Enough bone collagens are only supplemented, just can guarantee the rational proportion of bone ingredient.
Vitamin K2It is a kind of liposoluble vitamin, synthesis and secretion promoting bone growing and the bone mine of osteopontin can be increased
Change, reduce bone catabolism, to play the role for the treatment of osteoporosis.
Beneficial effects of the present invention：
D-Glucosamine Hydrochloride is used in combination with chondroitin sulfate, can delay and inhibit the degeneration of articular cartilage tissue
Become；Calcium and ossein are supplemented simultaneously, bone is made to have both intensity and toughness；Replenishing vitamins K2Can increase the synthesis of osteopontin with
Promoting bone growing and bone mineralising are secreted, bone catabolism is reduced；The capsule of the increase bone density of the present invention is suitble to mid-aged population
It takes, the bone density of user can be increased.
Description of the drawings
It in order to more clearly explain the embodiment of the invention or the technical proposal in the existing technology, below will be to institute in embodiment
Attached drawing to be used is needed to be briefly described, it should be apparent that, the accompanying drawings in the following description is only some implementations of the present invention
Example, for those of ordinary skill in the art, without creative efforts, can also obtain according to these attached drawings
Obtain other attached drawings.
Fig. 1 is the preparation method figure of the capsule of the increase bone density described according to embodiments of the present invention；
Note：It is 100,000 grades of clean areas in dotted line in Fig. 1.
Specific implementation mode
Following will be combined with the drawings in the embodiments of the present invention, and technical solution in the embodiment of the present invention carries out clear, complete
Site preparation describes, it is clear that described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.It is based on
Embodiment in the present invention, the every other embodiment that those of ordinary skill in the art are obtained belong to what the present invention protected
Range.
Embodiment 1
Increase the component of the capsule of bone density：
Calcium carbonate 210g
D-Glucosamine Hydrochloride 105g
Chondroitin sulfate 60g
Bone collagen powder 55g
The vitamin K that mass content is 0.2%2Powder 5g
Microcrystalline cellulose 12g
Magnesium stearate 3g.
Preparation process as shown in Figure 1,（1）Sieving：By calcium carbonate, D-Glucosamine Hydrochloride, chondroitin sulfate, gelatine
Former albumen powder, vitamin K2The vitamin K that mass content is 0.2%2Powder, microcrystalline cellulose, magnesium stearate cross 60 mesh sieve respectively；
（2）Mixing：Calcium carbonate, D-Glucosamine Hydrochloride, chondroitin sulfate, bone collagen powder after sieving is placed in mixing machine
Middle mixing 15min obtains mixed powder 1, by the vitamin K after sieving2Powder, microcrystalline cellulose, magnesium stearate are mixed
Close powder 2；Mixed powder 1 and mixed powder 2 are placed in mixing 20min in mixing machine and obtain total mixed powder；（3）：It is filling：By step（2）
The filling capsule of the total mixed powder of gained, it is 0.45g/ to adjust loading amount.
Embodiment 2
Increase the component of the capsule of bone density：
Calcium carbonate 160g
D-Glucosamine Hydrochloride 130g
Chondroitin sulfate 50g
Bone collagen powder 80g
The vitamin K that mass content is 0.2%2Powder3g
Microcrystalline cellulose 10g
Magnesium stearate 2g
The capsule for increasing bone density is prepared according to preparation process described in embodiment 1.
Embodiment 3
Increase the component of the capsule of bone density：
Calcium carbonate 220g
D-Glucosamine Hydrochloride 90g
Chondroitin sulfate 80g
Bone collagen powder 40g
The vitamin K that mass content is 0.2%2Powder8g
Microcrystalline cellulose 40g
Magnesium stearate 4g
The capsule for increasing bone density is prepared according to preparation process described in embodiment 1.
Increase bone substance density improving function zoopery
SPF grades of females are randomly divided into following five groups from newborn SD rats according to weight：Low calcium control group, increase bone density of the invention
Capsule 250mg/kg.bw groups, 500mg/kg.bw groups and 1500mg/kg.bw groups, carbon calcium control group, every group of 10 animals.
Three dosage groups orally pour into 525mg/ with the capsule solution gavage of the increase bone density of corresponding dosage, calcium carbonate control group
The calcium carbonate of kg.bw, low calcium control group is with distilled water gavage.Animal is subjected to calcium uptake experiment in 3 days after testing 3 weeks, survey is ingested
Amount, feed and excrement calcium content, calculate apparent calcium absorptivity.Experiment periods 13 weeks.The experiment dead animal in end takes bilateral femur：It measures
The bone density of right femur calcium content and left femur.
There was no significant difference compared with low calcium control group for the height of calcium uptake experimental result display three dosage groups of tested material,
High dose group experiment telophasic body is significantly higher than low calcium control group again.Tested material is low, middle dose group calcium apparent absorptivity is notable
Higher than calcium carbonate control group, show that the sample calcium absorptivity is higher.
Before the experiment of three dosage groups and calcium carbonate control group weight compared with low calcium control group without significant difference；It is middle and high
There was no significant difference compared with low calcium control group for the experiment opisthosoma weight of dosage group.Increase bone density three dosage groups of capsule and
The bone weight of the left femur bone density of calcium carbonate control group, right bone calcium content of femur, middle and high dosage group is more equal with low calcium control group
It dramatically increases.The right femur bone weight of tested material high dose group, weight and calcium carbonate control group relatively dramatically increase, remaining index with
Difference that calcium carbonate control group compares that there are no significant.
By evaluation criterion：The capsule calcium absorptivity of the increase bone density of the present invention is higher, has the function of increasing bone density.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all essences in the present invention
With within principle, any modification, equivalent replacement, improvement and so on should all be included in the protection scope of the present invention god.
Claims (3)
1. a kind of capsule increasing bone density, which is characterized in that be grouped as by the group of following parts by weight：
160-220 parts of calcium carbonate
90-130 parts of D-Glucosamine Hydrochloride
50-80 parts of chondroitin sulfate
40-80 parts of bone collagen powder
The vitamin K that mass content is 0.2%23-8 parts of powder
10-40 parts of microcrystalline cellulose
2-4 parts of magnesium stearate.
2. the capsule according to claim 1 for increasing bone density, which is characterized in that be grouped as by the group of following parts by weight：
210 parts of calcium carbonate
105 parts of D-Glucosamine Hydrochloride
60 parts of chondroitin sulfate
55 parts of bone collagen powder
Mass content is 0.2% vitamin K25 parts of powder
12 parts of microcrystalline cellulose
3 parts of magnesium stearate.
3. the preparation method of the capsule according to claim 1 for increasing bone density, which is characterized in that include the following steps：
（1）Sieving
It is 0.2% vitamin K by calcium carbonate, D-Glucosamine Hydrochloride, chondroitin sulfate, bone collagen powder, mass content2
Powder, microcrystalline cellulose, magnesium stearate cross 60 mesh sieve respectively；
（2）Mixing
Calcium carbonate, D-Glucosamine Hydrochloride, chondroitin sulfate, bone collagen powder after sieving is placed in mixing machine and is mixed
It closes 15min and obtains mixed powder 1, by the vitamin K after sieving2Powder, microcrystalline cellulose, magnesium stearate, which are uniformly mixed, obtains mixed powder
2；Mixed powder 1 and mixed powder 2 are placed in mixing 20min in mixing machine and obtain total mixed powder；
（3）It is filling
By step（2）The filling capsule of the total mixed powder of gained, it is 0.45g/ to adjust loading amount.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810630676.7A CN108619493A (en) | 2018-06-19 | 2018-06-19 | A kind of capsule increasing bone density |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810630676.7A CN108619493A (en) | 2018-06-19 | 2018-06-19 | A kind of capsule increasing bone density |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108619493A true CN108619493A (en) | 2018-10-09 |
Family
ID=63691921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810630676.7A Pending CN108619493A (en) | 2018-06-19 | 2018-06-19 | A kind of capsule increasing bone density |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108619493A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111135284A (en) * | 2019-12-11 | 2020-05-12 | 武汉跃莱健康产业有限公司 | Composition for improving bone mineral density and preparation method and application thereof |
| CN114288322A (en) * | 2021-12-30 | 2022-04-08 | 宣城柏维力生物工程有限公司 | Composition for improving articular cartilage health and production process thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101856128A (en) * | 2010-03-23 | 2010-10-13 | 无锡市天赐康生物科技有限公司 | Health food for increasing bone density and preparation method thereof |
| CN103736074A (en) * | 2013-11-21 | 2014-04-23 | 荣成百合生物技术有限公司 | Bone mineral density increase health capsule and preparation method thereof |
| CN105412569A (en) * | 2015-12-24 | 2016-03-23 | 福和寿（武汉）健康管理有限公司 | Composition for increasing bone mineral density and preparation and preparation method thereof |
| CN105942501A (en) * | 2016-05-03 | 2016-09-21 | 宣城柏维力生物工程有限公司 | Tablets capable of increasing bone density and preparation method of tablets |
-
2018
- 2018-06-19 CN CN201810630676.7A patent/CN108619493A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101856128A (en) * | 2010-03-23 | 2010-10-13 | 无锡市天赐康生物科技有限公司 | Health food for increasing bone density and preparation method thereof |
| CN103736074A (en) * | 2013-11-21 | 2014-04-23 | 荣成百合生物技术有限公司 | Bone mineral density increase health capsule and preparation method thereof |
| CN105412569A (en) * | 2015-12-24 | 2016-03-23 | 福和寿（武汉）健康管理有限公司 | Composition for increasing bone mineral density and preparation and preparation method thereof |
| CN105942501A (en) * | 2016-05-03 | 2016-09-21 | 宣城柏维力生物工程有限公司 | Tablets capable of increasing bone density and preparation method of tablets |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111135284A (en) * | 2019-12-11 | 2020-05-12 | 武汉跃莱健康产业有限公司 | Composition for improving bone mineral density and preparation method and application thereof |
| CN114288322A (en) * | 2021-12-30 | 2022-04-08 | 宣城柏维力生物工程有限公司 | Composition for improving articular cartilage health and production process thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101248882B (en) | Nutrition food product with promoting health of bones and bone arthrosis | |
| CN103082276B (en) | Composition for reducing sport injury and promoting sport injury repair | |
| CN101559218B (en) | Composition with function of increasing bone density | |
| CN102894372A (en) | Health-care food for increasing bone density and preparation method thereof | |
| US9610304B2 (en) | Bone paste composition | |
| NZ500025A (en) | Compounds containing aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine for the treatment of inflammation | |
| CN1903220A (en) | Health-care food with function of improving skeletal density and its prepn. method | |
| CN101695382A (en) | Calcium supplementing preparation with functions of improving bones and joints | |
| CN106235311A (en) | A kind of compositions promoting skeletal system health and application thereof | |
| WO2014072235A1 (en) | Collagen hydrolyzate and use thereof | |
| EP2273997A2 (en) | Method and composition for regenerating tissue with the aid of stem or bone marrow cells | |
| CN101322551A (en) | Combination for increasing bone density and repairing articular cartilage | |
| CN108619493A (en) | A kind of capsule increasing bone density | |
| CN106213492A (en) | A kind of lifter motion function also increases health-oriented products and the preparation method of bone density | |
| CN1947724A (en) | Compound amino-glucose hydrochloride, chondroitin sulfate effervescent, tablets prepn. method and use thereof | |
| CN104382005A (en) | Glucosamine chondroitin collagen tablet and preparation method thereof | |
| CN108720000A (en) | A kind of colostrum mineral salt calcium-supplementing preparation and preparation method thereof | |
| CN108112997A (en) | A kind of health-care food composition | |
| CN107096065A (en) | Composite nano-fiber membrane containing polysialic acids and preparation method and application | |
| CN1899300A (en) | Medicinal composition using amino glucose hydrochloride and chondroitin sulfate as active components and its preparing method and use | |
| US8337910B2 (en) | Herbal formulation for the treatment of bone fractures and osseous defects | |
| CN108815505A (en) | Improve the composition that middle-aged and the old's bone density and osteoarticular function avoid waist-leg from knotting | |
| CN104523804B (en) | A kind of capsule for increasing bone density and preparation method thereof | |
| CN108902987A (en) | Newborn mineral salt ammonia sugar chondroitin ties up D capsule | |
| KR101878599B1 (en) | Coprecipitation composition for accelerating the absorption and adjustment of the taste of methyl sulfonyl methanemannitol and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181009 |
|
| RJ01 | Rejection of invention patent application after publication |